(NASDAQ: TBPH) Theravance Biopharma's forecast annual revenue growth rate of 16.01% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 85.89%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.84%.
Theravance Biopharma's revenue in 2025 is $77,205,000.On average, 3 Wall Street analysts forecast TBPH's revenue for 2025 to be $6,161,855,649, with the lowest TBPH revenue forecast at $5,287,936,080, and the highest TBPH revenue forecast at $7,859,887,467. On average, 3 Wall Street analysts forecast TBPH's revenue for 2026 to be $5,837,025,290, with the lowest TBPH revenue forecast at $4,230,348,864, and the highest TBPH revenue forecast at $8,974,886,560.
In 2027, TBPH is forecast to generate $6,071,054,233 in revenue, with the lowest revenue forecast at $5,841,910,336 and the highest revenue forecast at $6,466,894,019.